Skip to content

武田制药

US · TAK #400 按市值排名 上市于 1970
19.67 +0.22 +1.13%
实时 - 追踪5344个代码 - 心跳于3秒前 · 2026-10-16 17:23

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了5家。
  • 机构持股总比例下降了2.0个百分点。

机构持股

机构持股比例
50.30% -2.04pp
机构数量
680 -5
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund44.76%
Public Company1.58%
Sovereign Wealth Fund1.29%
Private Company1.24%
Hedge Fund0.69%
Government Pension Fund0.49%
Insurance Company0.20%
Individual/Insider0.12%
Other49.60%

主要股东 截至 2026-09-15

BlackRock 9.15% · 292.05M 股
Nomura Asset Management 4.46% · 142.29M 股
Vanguard Capital Management, LLC 3.88% · 123.88M 股
Sumitomo Mitsui Trust Asset Management 3.11% · 99.22M 股
Capital Research 2.90% · 92.61M 股
Other 77.08%
Amova Asset Management 2.14% · 68.46M 股
Daiwa Asset Management 2.00% · 63.95M 股
Nissay Asset Management Corporation 1.55% · 49.50M 股
Sumitomo Mitsui Financial Group, Inc. 1.39% · 44.28M 股
Norges Bank Investment Management 1.29% · 41.31M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 22次买入 · 28次卖出

姓名职务持股比例
Christophe P. Weber President, CEO & Representative Director 0.05%
Andrew S. Plump President of Research & Development and Representative Director 0.02%
Julie Kim President of the U.S. Business Unit & U.S. Country Head 0.01%
Giles Platford President of the Plasma-Derived Therapies Business Unit 0.01%
Teresa Marie Bitetti President of the Global Oncology Business Unit 0.01%
Marcello Pignagnoli Agosti Global Business Development Officer 0.00%
Gabriele Ricci Chief Data & Technology Officer 0.00%
Lauren Duprey Chief Human Resources Officer 0.00%
Milano Furuta President of Japan Pharma Business Unit 0.00%
Farajallah Awny Botros Chief Medical Officer 0.00%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-13 Lauren Duprey Chief Human Resources Officer Open Market Disposition -34,535 $18.54
2026-09-01 Andrew S. Plump President of Research & Development and Representative Director Automatic Disposition -116,191 $18.49
2026-08-18 Andrew S. Plump President of Research & Development and Representative Director Automatic Disposition -19,651 $18.49
2026-08-17 Nicola Greenway -- Open Market Disposition -12,980 $18.11
2026-08-13 Nicola Greenway -- Intent to Sell (Form 144) -12,980 $17.39
2026-08-10 Elaine Shannon President of Global Supply & Quality Open Market Disposition -20,363 $17.55
2026-08-09 Andrew S. Plump President of Research & Development and Representative Director Private Disposition -165,393 $17.10
2026-08-09 Giles Platford President of the Plasma-Derived Therapies Business Unit Private Disposition -31,083 $17.10
2026-08-09 Farajallah Awny Botros Chief Medical Officer Private Disposition -14,006 $17.10
2026-08-09 Julie Kim President of the U.S. Business Unit & U.S. Country Head Private Disposition -89,090 $17.10
2026-08-09 Teresa Marie Bitetti President of the Global Oncology Business Unit Private Disposition -50,012 $17.10
2026-08-09 Ramy Ibrahim -- Private Disposition -7,277 $17.10
2026-08-09 Lauren Duprey Chief Human Resources Officer Private Disposition -47,586 $17.10
2026-08-09 Gabriele Ricci Chief Data & Technology Officer Private Disposition -25,088 $17.10
2026-08-09 Marcello Pignagnoli Agosti Global Business Development Officer Private Disposition -22,957 $17.10
2026-08-09 Elaine Shannon President of Global Supply & Quality Private Disposition -3,978 $17.10
2026-08-09 Natalie Furney Global General Counsel Private Disposition -30,868 $17.10
2026-08-09 Rhonda Pacheco President of U.S. Business Unit Private Disposition -16,901 $17.10
2026-08-09 Nicola Greenway -- Private Disposition -6,774 $17.10
2026-08-09 Nicola Greenway -- Open Market Disposition -34,603 $17.50–17.51

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 17:23:15 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

武田制药 讨论区 0 条评论

发表评论